 SHANGHAI and HONG KONG, May 12, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, today announced that Chinas National Medical Products Administration NMPA has approved the Investigational New Drug IND application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor XPOVIO in the treatment of advanced or recurrent endometrial cancer the SIENDO trial. Endometrial cancer is a common gynecologic malignancy which frequently occurs in women of reproductive age. 